Navigation Links
Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry Eye
Date:4/15/2009

EVRY, France, April 15 /PRNewswire/ -- Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat(R), its formulation of Cyclosporine. The results demonstrate statistically significant improvement with signs and symptoms in patients suffering from moderate-to-severe dry eye syndrome.

For this dry eye clinical trial, Novagali worked with Ora, Inc., a leading global clinical research and development organization located in Andover, MA, USA. This phase II, multi-centre, randomized, double-masked, vehicle controlled study of 132 patients evaluated the safety and efficacy of Cyclokat(R) applied once-a-day over three months. Ora's proprietary Controlled Adverse Environment (CAE) clinical model was used in this study conducted in the US.

Efficacy was observed post-CAE as well as pre-CAE (environmental comparisons following selection and enrollment of patients utilizing the CAE). Cyclokat(R) demonstrated significant treatment effect on multiple efficacy variables for both signs and symptoms at Month 1 and Month 3. . These findings confirm potential clinical interest of Cyclokat(R) for the treatment of dry eye syndrome.

"We are very enthusiastic about the results of this new trial demonstrating efficacy on both dry eye signs and symptoms" said Jerome Martinez, CEO of Novagali "These are promising results which make us confident in the success of our ongoing Phase III which outcomes are expected 4Q2009".

A pivotal Phase III trial is ongoing in Europe and patient recruitment has been already completed.

Cyclokat(R) is a proprietary ophthalmic emulsion enabling an optimal penetration of Cyclosporine in tissues of the eye surface that benefit from Novasorb(R), Novagali(R) cationic emulsion technology.

About Novagali Pharma : http://www.novagali.com

Novagali Pharma is an ophthalmic pharmaceutical company that develops and commercializes innovative products. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), for treatment of vernal keratoconjunctivitis, Cyclokat(R), for the treatment of moderate-to-severe dry eye syndrome and Cortiject(R) for the treatment of diabetic retinopathies. Cationorm(R), indicated for dry eye symptoms is commercialized in France since April 2008. Founded in 2000, Novagali Pharma is based in the Genopole biocluster in Evry (France).

In 2009, Frost & Sullivan recognized Novagali with the North American Award for Industry Innovation & Advancement of the Year, for its two proprietary emulsion technology platforms, Novasorb(R) and Eyeject(R).

About Ora, Inc.

Ora is the leading independent ophthalmic drug and device development firm, with more than 27 NDA approvals for its clients during its 30-year history. Ora provides technology-based, concept-to-market services and solutions that accelerate development timelines while maintaining the highest standards for clinical research.


'/>"/>
SOURCE Novagali Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma
2. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
3. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
4. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
5. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
6. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
7. Strativa Pharmaceuticals Provides Product Pipeline Update
8. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
9. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
10. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017 Newborns are highly ... most vaccines because their young immune systems typically ... Children,s Hospital report achieving strong vaccine responses in ... model before human trials — by adding compounds ... In two simultaneous papers, they also describe improved ...
(Date:3/23/2017)... 2017  The goal of the pilot is ... track prescription drugs as they are distributed in ... requirements from US FDA to better protect consumers by ... Blockchain startup Chronicled, which links the ... blockchain technology and recently raised $6.25M, and the LinkLab, ...
(Date:3/23/2017)... , March 23, 2017 /PRNewswire/ - INVICTUS MD STRATEGIES ... FRA: 8IS) Invictus MD announces that AB Laboratories Inc. ... its licensed production facility under the Access to Cannabis ... Hamilton, Ontario . The facility, ... October 2016, is currently operating at half capacity, with ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... , ... “The Adventures of Joey, The Dog Who Barks at Puddles”: a ... to the fullest, as God intended. “The Adventures of Joey, The Dog Who Barks ... pursuing her passion for writing, especially about truth and human behavior. , Published by ...
(Date:3/23/2017)... ... March 23, 2017 , ... The physicians of KSF ... the greater Houston Area. The new location is located at 2255 E. Mossy Oaks ... Springwoods Village. This newest location will provide patients living in the north Houston area ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Convention Center at 10 North Broadway Avenue, will be an educational and exciting ... practical instruction in the management of chronic pain. , Oklahoma is in a ...
(Date:3/23/2017)... ... March 23, 2017 , ... 82% of adults are unaware of the dangers that infectious ... their teeth the minimum two times a day that dentists recommend. The ramifications of improper ... hours of school and adults missing 164 million hours of work each year due to ...
(Date:3/23/2017)... ... March 23, 2017 , ... Benefits delivery trailblazer, ... app and centralized benefits dashboard solving one of the top frustrations in employee ... For the first time, employees can access up-to-date information and account balances for ...
Breaking Medicine News(10 mins):